A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Recruiting · NCT07372625 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | Advanced Solid Tumors; TP53 Y220C Mutation | Recruiting | Phase 1 | 2026-08-12 | NCT07372625 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| PMV Pharmaceuticals, Inc | 3 |
| SCRI Development Innovations, LLC | 7 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Florida Cancer Specialists | Orlando | United States | 8 |
| HealthOne Denver | Denver | United States | 1 |
| NEXT Oncology | San Antonio | United States | 70 |
| SCRI at Mary Crowley | Dallas | United States | 6 |
| Scri Oncology Partners | Nashville | United States | 156 |